KU812 cell line
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats KU812 cell line as ChEMBL target CHEMBL613997. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why KU812 cell line matters
KU812 cell line is reviewed as KU812 cell line; the current evidence base includes 32 approved drugs, 178 compounds, and 57 assays, with lead potency reaching pChEMBL 10.0.
KU812 cell line
Review this target as KU812 cell line.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 32 approved drugs, 178 compounds, and 57 assays for this target. The dominant activity type is IC50. CHEMBL5416410 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL5416410 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why KU812 cell line matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5416410
|
10.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL5093894
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL1171837
|
10.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL5089813
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL5089020
|
9.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
SELUMETINIB
CHEMBL1614701
|
2020 |
|
|
AFATINIB
CHEMBL1173655
|
2013 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
AXITINIB
CHEMBL1289926
|
2012 |
|
|
NILOTINIB
CHEMBL255863
|
2007 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
IMATINIB
CHEMBL941
|
2001 |
|
|
IMATINIB MESYLATE
CHEMBL1642
|
2001 |
|
|
SIROLIMUS
CHEMBL413
|
1999 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
TRETINOIN
CHEMBL38
|
1971 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |